StreetAccount Summary - Trading higher/lower: Japan mid-day
Santen Pharmaceutical downgraded to hold from buy at Jefferies (¥1665.0000, 0)
Santen Pharmaceutical reports Q1 core net income attributable ¥7.64B vs FactSet ¥8.11B (¥1665.0000, 0)
Santen Pharmaceutical forms medium-tern plan for FY25-29: targets Core operating profit ¥80B in FY29 (21-May post-Japan close) (¥1570.5000, +47)
Santen Pharmaceutical to launch up-to-¥35.0B buyback, to run from 22-May through 5-Nov (¥1424.0000, 0)
Santen Pharmaceutical reports Q4 core net income attributable ¥11.28B vs year-ago ¥8.91B (¥1424.0000, 0)
StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (23 total)
Powered by FactSet Research Systems Inc.